Clinigen
Clinigen Group plc, headquartered in the United Kingdom, is a leading global pharmaceutical and services company specialising in the provision of access to medicines. Founded in 2010, Clinigen has rapidly established itself in the healthcare industry, focusing on unlicensed and niche products, clinical trial services, and the management of complex supply chains. With a strong presence in Europe, North America, and Asia, Clinigen offers unique solutions that bridge the gap between pharmaceutical companies and patients. Their core services include the provision of clinical trial supplies and the management of access programmes, ensuring that patients receive critical treatments when they need them most. Clinigen's commitment to patient access and innovative solutions has positioned it as a trusted partner in the global healthcare landscape, achieving significant milestones in expanding its product offerings and market reach.
DitchCarbon Score
How does Clinigen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Clinigen's score of 53 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Clinigen's reported carbon emissions
In 2022, Clinigen Limited reported total carbon emissions of approximately 72,050,000 kg CO2e, comprising 44,600,000 kg CO2e from Scope 1, 2,900,000 kg CO2e from Scope 2, and 24,550,000 kg CO2e from Scope 3 emissions. The company has set ambitious targets to reduce its greenhouse gas emissions, committing to a 42% reduction in absolute Scope 1 and 2 emissions by 2030, using FY2023 as the base year. Additionally, Clinigen aims to achieve a 42% reduction in Scope 3 emissions within the same timeframe. Long-term goals include a significant 90% reduction in absolute emissions across all scopes by 2040, alongside a commitment to reach net-zero emissions by the same year. These targets align with the Science Based Targets initiative (SBTi) and reflect Clinigen's dedication to addressing climate change within the pharmaceutical and biotechnology sector. The company's climate strategy is designed to ensure compliance with industry standards and contribute to global efforts to limit temperature rise to 1.5°C.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Clinigen is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
